Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study

  • Mathias Fiedler
  • Patty Renner
  • Jürgen Schubert
  • Florian Weber
  • Arndt Hartmann
  • Heinrich Iro
  • Veronika Vielsmeier
  • Christopher Bohr
  • Michael Gerken
  • Torsten E. Reichert
  • Tobias EttlEmail author
Original Article



The aim of this study was to investigate the predictive value of the biomarkers FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas.

Material and methods

Immunohistochemical staining of FHIT, p27, and pERK1/ERK2 of 265 patients with salivary gland carcinomas was conducted, and associations with clinico-histopathological data, overall survival, and disease-specific survival were examined.


Expression of FHIT (quick score 98.7 vs. 206.4) and p27 (QS 187.3 vs. 244.8) was significantly lower in carcinomas compared to non-tumor control tissue. Loss of FHIT frequently occurred in ACC (55.2%), SDC (68.2%), and SCC (100%). In the totality of tumors, loss of FHIT expression was found in 46.7% (106/227) and was significantly associated with advanced T stage and UICC stage, high-grade histology, loss of p27, PI3K, and survivin. FHIT positivity went along with significantly better overall and disease-specific survival. Negativity of p27 occurred in 28.7% (70/244) of tumors, particularly in SDC (54.4%) and SCC (50%). In the totality of tumors, p27 was associated with advanced patient age, high-grade histology, PI3K, survivin as well as better overall and disease-specific survival (p < 0.05). Positive pERK1/ERK2 expression correlated with positive survivin expression but did not affect overall survival in the totality of tumors. In mucoepidermoid carcinomas, pERK1/ERK2 expression was associated with low-grade malignancy, positive nuclear survivin, and better disease-specific survival.


Loss of FHIT and p27 characterizes aggressive tumor growth and unfavorable prognosis in salivary gland cancer.

Clinical relevance

The results may help to stratify patient-specific therapies according to individual tumor characteristics.


Salivary gland carcinoma FHIT p27 pERK1/ERK2 



We wish to thank Rudolf Jung for his excellent immunohistochemical stainings.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent is not required.


  1. 1.
    Speight P, Barrett A (2002) Salivary gland tumours. Oral Dis 8:229–240CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    El-Naggar AK (2017) What is new in the World Health Organization 2017 histopathology classification? Curr Treat Options in Oncol 18:43. CrossRefGoogle Scholar
  3. 3.
    Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM (2002) FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 3:748–754. CrossRefPubMedGoogle Scholar
  4. 4.
    Dincer N, Tezel GG, Sungur A, Himmetoglu C, Huebner K, Guler G (2010) Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland. Oral Oncol 46:195–199. CrossRefPubMedGoogle Scholar
  5. 5.
    Semba S, Trapasso F, Fabbri M, McCorkell KA, Volinia S, Druck T, Iliopoulos D, Pekarsky Y, Ishii H, Garrison PN, Barnes LD, Croce CM, Huebner K (2006) Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 25:2860–2872. CrossRefPubMedGoogle Scholar
  6. 6.
    Okabe M, Inagaki H, Murase T, Inoue M, Nagai N, Eimoto T (2001) Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland. Mod Pathol 14:1008–1014CrossRefPubMedGoogle Scholar
  7. 7.
    Chu IM, Hengst L, Slingerland JM (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8:253–267. CrossRefPubMedGoogle Scholar
  8. 8.
    Ben-Izhak O, Akrish S, Gan S, Nagler RM (2009) p27 and salivary cancer. Cancer Immunol Immunother 58:469–473. CrossRefPubMedGoogle Scholar
  9. 9.
    Handra-Luca A, Ruhin B, Lesty C, Fouret P (2006) P27, SKP2, and extra-cellular signal-related kinase signalling in human salivary gland mucoepidermoid carcinoma. Oral Oncol 42:1005–1010. CrossRefPubMedGoogle Scholar
  10. 10.
    Donovan JC, Milic A, Slingerland JM (2001) Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276:40888–40895. CrossRefPubMedGoogle Scholar
  11. 11.
    Burotto M, Chiou VL, Lee JM, Kohn EC (2014) The MAPK pathway across different malignancies: a new perspective. Cancer 120:3446–3456. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Barnes L, Eveson J, Reichart P, Sidransky D (2005) Pathology and genetics of head and neck tumours. World Health Organization classification of Tumours. IARC, LyonGoogle Scholar
  13. 13.
    Ettl T, Schwarz-Furlan S, Haubner F, Müller S, Zenk J, Gosau M, Reichert TE, Zeitler K (2012) The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol 48:822–830CrossRefPubMedGoogle Scholar
  14. 14.
    Ettl T, Stiegler C, Zeitler K, Agaimy A, Zenk J, Reichert TE, Gosau M, Kühnel T, Brockhoff G, Schwarz S (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43:921–931CrossRefPubMedGoogle Scholar
  15. 15.
    Milanes-Yearsley M, Hammond ME, Pajak TF, Cooper JS, Chang C, Griffin T, Nelson D, Laramore G, Pilepich M (2002) Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol 15:1366–1373. CrossRefPubMedGoogle Scholar
  16. 16.
    Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche O, Reid J, Stone S, Penault-Llorca F (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924–5930. CrossRefPubMedGoogle Scholar
  17. 17.
    Cao J, Li W, Xie J, Du H, Tang W, Wang H, Chen X, Xiao W, Li Y (2006) Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication. Surg Oncol 15:223–233. CrossRefPubMedGoogle Scholar
  18. 18.
    Woenckhaus M, Merk J, Stoehr R, Schaeper F, Gaumann A, Wiebe K, Hartmann A, Hofstaedter F, Dietmaier W (2008) Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 39:126–136. CrossRefPubMedGoogle Scholar
  19. 19.
    Dumon K, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato E, Williams N, Baffa R, During M, Huebner K, Croce C (2001) Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer1. Cancer Res 61:4827–4836PubMedGoogle Scholar
  20. 20.
    Huang Q, Liu Z, Xie F, Liu C, Shao F, Zhu CL, Hu S (2014) Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathway. ScientificWorldJournal 2014:179698. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Li F, Yang J, Ramnath N, Javle MM, Tan D (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509–512. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Zhao P, Meng Q, Liu LZ, You YP, Liu N, Jiang BH (2010) Regulation of survivin by PI3K/Akt/p70S6K1 pathway. Biochem Biophys Res Commun 395:219–224. CrossRefPubMedGoogle Scholar
  23. 23.
    Sarli L, Bottarelli L, Azzoni C, Campanini N, Di Cola G, Barilli AL, Marchesi F, Mazzeo A, Salvemini C, Morari S, Di Mauro D, Donadei E, Necchi F, Roncoroni L, Bordi C (2006) Loss of p27 expression and microsatellite instability in sporadic colorectal cancer. Surg Oncol 15:97–106. CrossRefPubMedGoogle Scholar
  24. 24.
    Handra-Luca A, Bilal H, Bertrand J-C, Fouret P (2003) Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland Mucoepidermoid carcinoma. Am J Pathol 163:957–967. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Deschenes-Simard X, Kottakis F, Meloche S, Ferbeyre G (2014) ERKs in cancer: friends or foes? Cancer Res 74:412–419. CrossRefPubMedGoogle Scholar
  26. 26.
    Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Muller V, Loning T (2005) Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 92:2206–2215. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lujan B, Hakim S, Moyano S, Nadal A, Caballero M, Diaz A, Valera A, Carrera M, Cardesa A, Alos L (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510–516. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Chen X, Duan N, Zhang C, Zhang W (2016) Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. J Cancer 7:314–323. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ettl T, Baader K, Stiegler C, Muller M, Agaimy A, Zenk J, Kuhnel T, Gosau M, Zeitler K, Schwarz S, Brockhoff G (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719–726. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O (2008) Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 53:567–577. CrossRefPubMedGoogle Scholar
  31. 31.
    Ach T, Zeitler K, Schwarz-Furlan S, Baader K, Agaimy A, Rohrmeier C, Zenk J, Gosau M, Reichert TE, Brockhoff G, Ettl T (2013) Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch 462:65–72. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Mathias Fiedler
    • 1
  • Patty Renner
    • 1
  • Jürgen Schubert
    • 2
  • Florian Weber
    • 3
  • Arndt Hartmann
    • 4
  • Heinrich Iro
    • 5
  • Veronika Vielsmeier
    • 6
  • Christopher Bohr
    • 6
  • Michael Gerken
    • 7
  • Torsten E. Reichert
    • 1
  • Tobias Ettl
    • 1
    Email author
  1. 1.Department of Oral and Maxillofacial SurgeryUniversity Hospital RegensburgRegensburgGermany
  2. 2.BayreuthGermany
  3. 3.Department of PathologyUniversity Hospital RegensburgRegensburgGermany
  4. 4.Institute of PathologyUniversity Hospital of ErlangenErlangenGermany
  5. 5.Department of Otorhinolaryngology and Head and Neck SurgeryUniversity of Erlangen-NurembergErlangenGermany
  6. 6.Department of OtorhinolaryngologyUniversity Hospital RegensburgRegensburgGermany
  7. 7.Center of Tumor RegistryUniversity of RegensburgRegensburgGermany

Personalised recommendations